Immune Checkpoint Combination Agent
The Immune Checkpoint Combination Agent analyzes tumor molecular profiles to predict optimal immune checkpoint inhibitor (ICI) combinations. It integrates TME characterization, checkpoint expression, resistance mechanisms, and clinical evidence for rational immunotherapy combination design.
When to Use This Skill
- When selecting checkpoint inhibitor combinations for individual patients.
- To predict response to ICI combinations (PD-1/PD-L1 + CTLA-4, TIGIT, LAG-3).
- For identifying resistance mechanisms suggesting specific combinations.
- When analyzing tumor microenvironment to guide combination selection.
- To match patients to combination immunotherapy clinical trials.
Core Capabilities
Checkpoint Expression Profiling: Quantify expression of PD-1, PD-L1, CTLA-4, TIGIT, LAG-3, TIM-3, and others.
TME Characterization: Classify tumors as "hot" (inflamed), "excluded", or "cold" (desert) for combination rationale.
Resistance Mechanism Analysis: Identify primary and acquired resistance patterns.
Combination Prediction: ML models predicting response to specific checkpoint combinations.
Synergy Scoring: Evaluate potential synergies based on mechanism of action overlap.
Clinical Evidence Integration: Match combinations to published efficacy data.
Checkpoint Inhibitor Landscape
| Target |
Approved Agents |
Mechanism |
Combination Rationale |
| PD-1 |
Pembrolizumab, Nivolumab |
Block T-cell inhibition |
Backbone therapy |
| PD-L1 |
Atezolizumab, Durvalumab |
Block tumor immune evasion |
Alternative backbone |
| CTLA-4 |
Ipilimumab, Tremelimumab |
Enhance T-cell priming |
Non-redundant to PD-1 |
| LAG-3 |
Relatlimab |
Block exhausted T-cells |
PD-1 refractory |
| TIGIT |
Tiragolumab |
Block NK/T suppression |
NK cell engagement |
| TIM-3 |
Multiple in trials |
Terminal exhaustion |
Highly exhausted TME |
Workflow
Input: Tumor RNA-seq, IHC markers, TMB/MSI status, clinical data.
Checkpoint Profiling: Quantify checkpoint ligand/receptor expression.
TME Classification: Determine immune infiltration pattern.
Resistance Analysis: Identify potential resistance mechanisms.
Combination Scoring: Rank combinations by predicted efficacy.
Evidence Matching: Link to clinical trial data.
Output: Ranked combinations, rationale, supporting evidence, trial matches.
Example Usage
User: "Recommend optimal checkpoint inhibitor combination for this melanoma patient based on their tumor profile."
Agent Action:
python3 Skills/Immunology_Vaccines/Immune_Checkpoint_Combination_Agent/ici_combination.py \
--rnaseq tumor_expression.tsv \
--ihc pd-l1_tps_60.json \
--mutations tumor_mutations.maf \
--tmb 12.5 \
--msi stable \
--tumor_type melanoma \
--prior_treatment pembrolizumab \
--output ici_recommendations.json
TME-Based Combination Rationale
Inflamed ("Hot") Tumors:
- High TIL infiltration
- PD-L1 high
- Respond to anti-PD-1 monotherapy
- Add CTLA-4 for improved depth
Excluded Tumors:
- TILs at margin, not infiltrating
- Physical/chemical barriers
- Consider anti-CTLA-4 for priming
- Add chemotherapy for barrier disruption
Desert ("Cold") Tumors:
- Low TIL infiltration
- Low PD-L1
- Need to induce inflammation first
- Consider chemo, radiation, or vaccines + ICI
Resistance Mechanisms and Solutions
| Mechanism |
Biomarkers |
Combination Strategy |
| Alternative checkpoints |
LAG-3+, TIGIT+, TIM-3+ |
Add second checkpoint |
| WNT/β-catenin |
CTNNB1 mutations |
Poor ICI candidate |
| IFN signaling loss |
JAK1/2, B2M mutations |
Limited benefit |
| MHC loss |
HLA-A/B/C loss |
NK-engaging therapies |
| T-cell exclusion |
TGF-β high |
TGF-β inhibitor combination |
AI/ML Models
Response Prediction:
- Multi-modal model (expression + mutations + clinical)
- Trained on TCGA + clinical trial data
- AUC 0.72-0.80 for response
Synergy Prediction:
- Network-based combination scoring
- Mechanistic pathway analysis
- Clinical validation integration
Combination Evidence Database
| Combination |
Indication |
Key Trial |
Benefit |
| Nivo + Ipi |
Melanoma |
CheckMate-067 |
OS improvement |
| Nivo + Rela |
Melanoma |
RELATIVITY-047 |
PFS improvement |
| Atezo + Tira |
NSCLC |
CITYSCAPE |
PFS improvement (PD-L1 high) |
| Durva + Treme |
HCC |
HIMALAYA |
OS improvement |
Prerequisites
- Python 3.10+
- scikit-learn, XGBoost for ML
- Gene signature databases
- Clinical evidence database
Related Skills
- TCell_Exhaustion_Analysis_Agent - For exhaustion profiling
- Tumor_Microenvironment - For TME characterization
- Neoantigen_Vaccine_Agent - For vaccine combinations
Clinical Considerations
- Toxicity: Combinations increase irAE risk
- Sequencing: Optimal order of agents
- Biomarkers: TMB, PD-L1, MSI as selection criteria
- Cost: Combination therapy costs
Author
AI Group - Biomedical AI Platform
1---2name: immune-checkpoint-combination-agent3description: AI-powered analysis for predicting optimal immune checkpoint inhibitor combinations based on tumor microenvironment, biomarkers, and molecular profiling.4---56<!--7# COPYRIGHT NOTICE8# This file is part of the "Universal Biomedical Skills" project.9# Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>10# All Rights Reserved.11#12# This code is proprietary and confidential.13# Unauthorized copying of this file, via any medium is strictly prohibited.14#15# Provenance: Authenticated by MD BABU MIA1617-->18192021# Immune Checkpoint Combination Agent2223The **Immune Checkpoint Combination Agent** analyzes tumor molecular profiles to predict optimal immune checkpoint inhibitor (ICI) combinations. It integrates TME characterization, checkpoint expression, resistance mechanisms, and clinical evidence for rational immunotherapy combination design.2425## When to Use This Skill2627* When selecting checkpoint inhibitor combinations for individual patients.28* To predict response to ICI combinations (PD-1/PD-L1 + CTLA-4, TIGIT, LAG-3).29* For identifying resistance mechanisms suggesting specific combinations.30* When analyzing tumor microenvironment to guide combination selection.31* To match patients to combination immunotherapy clinical trials.3233## Core Capabilities34351. **Checkpoint Expression Profiling**: Quantify expression of PD-1, PD-L1, CTLA-4, TIGIT, LAG-3, TIM-3, and others.36372. **TME Characterization**: Classify tumors as "hot" (inflamed), "excluded", or "cold" (desert) for combination rationale.38393. **Resistance Mechanism Analysis**: Identify primary and acquired resistance patterns.40414. **Combination Prediction**: ML models predicting response to specific checkpoint combinations.42435. **Synergy Scoring**: Evaluate potential synergies based on mechanism of action overlap.44456. **Clinical Evidence Integration**: Match combinations to published efficacy data.4647## Checkpoint Inhibitor Landscape4849| Target | Approved Agents | Mechanism | Combination Rationale |50|--------|-----------------|-----------|----------------------|51| PD-1 | Pembrolizumab, Nivolumab | Block T-cell inhibition | Backbone therapy |52| PD-L1 | Atezolizumab, Durvalumab | Block tumor immune evasion | Alternative backbone |53| CTLA-4 | Ipilimumab, Tremelimumab | Enhance T-cell priming | Non-redundant to PD-1 |54| LAG-3 | Relatlimab | Block exhausted T-cells | PD-1 refractory |55| TIGIT | Tiragolumab | Block NK/T suppression | NK cell engagement |56| TIM-3 | Multiple in trials | Terminal exhaustion | Highly exhausted TME |5758## Workflow59601. **Input**: Tumor RNA-seq, IHC markers, TMB/MSI status, clinical data.61622. **Checkpoint Profiling**: Quantify checkpoint ligand/receptor expression.63643. **TME Classification**: Determine immune infiltration pattern.65664. **Resistance Analysis**: Identify potential resistance mechanisms.67685. **Combination Scoring**: Rank combinations by predicted efficacy.69706. **Evidence Matching**: Link to clinical trial data.71727. **Output**: Ranked combinations, rationale, supporting evidence, trial matches.7374## Example Usage7576**User**: "Recommend optimal checkpoint inhibitor combination for this melanoma patient based on their tumor profile."7778**Agent Action**:79```bash80python3 Skills/Immunology_Vaccines/Immune_Checkpoint_Combination_Agent/ici_combination.py \81 --rnaseq tumor_expression.tsv \82 --ihc pd-l1_tps_60.json \83 --mutations tumor_mutations.maf \84 --tmb 12.5 \85 --msi stable \86 --tumor_type melanoma \87 --prior_treatment pembrolizumab \88 --output ici_recommendations.json89```9091## TME-Based Combination Rationale9293**Inflamed ("Hot") Tumors**:94- High TIL infiltration95- PD-L1 high96- Respond to anti-PD-1 monotherapy97- Add CTLA-4 for improved depth9899**Excluded Tumors**:100- TILs at margin, not infiltrating101- Physical/chemical barriers102- Consider anti-CTLA-4 for priming103- Add chemotherapy for barrier disruption104105**Desert ("Cold") Tumors**:106- Low TIL infiltration107- Low PD-L1108- Need to induce inflammation first109- Consider chemo, radiation, or vaccines + ICI110111## Resistance Mechanisms and Solutions112113| Mechanism | Biomarkers | Combination Strategy |114|-----------|------------|---------------------|115| Alternative checkpoints | LAG-3+, TIGIT+, TIM-3+ | Add second checkpoint |116| WNT/β-catenin | CTNNB1 mutations | Poor ICI candidate |117| IFN signaling loss | JAK1/2, B2M mutations | Limited benefit |118| MHC loss | HLA-A/B/C loss | NK-engaging therapies |119| T-cell exclusion | TGF-β high | TGF-β inhibitor combination |120121## AI/ML Models122123**Response Prediction**:124- Multi-modal model (expression + mutations + clinical)125- Trained on TCGA + clinical trial data126- AUC 0.72-0.80 for response127128**Synergy Prediction**:129- Network-based combination scoring130- Mechanistic pathway analysis131- Clinical validation integration132133## Combination Evidence Database134135| Combination | Indication | Key Trial | Benefit |136|-------------|------------|-----------|---------|137| Nivo + Ipi | Melanoma | CheckMate-067 | OS improvement |138| Nivo + Rela | Melanoma | RELATIVITY-047 | PFS improvement |139| Atezo + Tira | NSCLC | CITYSCAPE | PFS improvement (PD-L1 high) |140| Durva + Treme | HCC | HIMALAYA | OS improvement |141142## Prerequisites143144* Python 3.10+145* scikit-learn, XGBoost for ML146* Gene signature databases147* Clinical evidence database148149## Related Skills150151* TCell_Exhaustion_Analysis_Agent - For exhaustion profiling152* Tumor_Microenvironment - For TME characterization153* Neoantigen_Vaccine_Agent - For vaccine combinations154155## Clinical Considerations1561571. **Toxicity**: Combinations increase irAE risk1582. **Sequencing**: Optimal order of agents1593. **Biomarkers**: TMB, PD-L1, MSI as selection criteria1604. **Cost**: Combination therapy costs161162## Author163164AI Group - Biomedical AI Platform165166167<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->
bg-szy